Asset Details
Do you wish to reserve the book?
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
Do you wish to request the book?
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron
2018
Overview
This retrospective analysis evaluated chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention.
At a community practice, CINV-related hydration per chemotherapy cycle was determined following highly (HEC) or moderately emetogenic chemotherapy (MEC) and a guideline-recommended antiemetic regimen: neurokinin 1 receptor antagonist, dexamethasone and either palonosetron only, GERSC only, or palonosetron switched to GERSC.
Palonosetron-only patients (n = 93) had a significantly higher mean (standard deviation) hydration rate (0.9 [1.1]) than GERSC-only patients (n = 91) (0.3 [0.6]) (p < 0.0001). Switched patients' (n = 48) hydration rates were significantly higher in the HEC subgroup with palonosetron (0.7 [1.2]) versus GERSC (0.5 [1.0]) (p = 0.028).
GERSC in a three-drug antiemetic regimen may reduce hydration needs following HEC or MEC.
Publisher
Future Medicine Ltd
Subject
/ Aged
/ Antiemetics - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ chemotherapy-induced nausea and vomiting (CINV)
/ Dexamethasone - therapeutic use
/ Female
/ Granisetron - therapeutic use
/ granisetron extended-release subcutaneous (GERSC)
/ Humans
/ Isoquinolines - therapeutic use
/ Male
/ Nausea
/ Nausea - prevention & control
/ Oncology
/ Patients
/ Practice Guidelines as Topic
/ Quinuclidines - therapeutic use
/ Serotonin Antagonists - therapeutic use
/ Vomiting
